Chemotherapy-Induced Peripheral Neuropathy - Additional Evaluation in Breast Cancer Survivors

Starting soon · Not applicable

Conditions studied: Breast Cancer

In brief

The main goal of this trial is to identify the optimal cut-off score of a Scoring System to discriminate between mild chemotherapy-induced peripheral neuropathy (CIPN) and no CIPN in breast cancer survivors previously treated with taxane-based chemotherapy and adjuvant radiotherapy.

Key facts

Study ID

NCT07604441

Run by

University Hospital Schleswig-Holstein

People needed

28

Starts

2026-06-01

Expected to finish

2026-08-31

Last updated by the study team

2026-05-22

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Histologically proven breast cancer
• Previous treatment with taxane-based chemotherapy followed by adjuvant radiotherapy
• Mild or no CIPN according to the Total Neuropathy Score
• Female gender
• Age ≥18 years
• Written informed consent
• Capacity of the patient to consent

You may not qualify if…

• Disease-related skin disorders of the lower extremities (e.g., related to skin infections, bullous dermatoses, dermatitis, papulo-squamous skin disorders, or urticaria/erythema)
• Pregnancy, Lactation
• Expected non-compliance

Where it is running

• Department of Radiation Oncology, University of Luebeck — Lübeck, Schleswig-Holstein, Germany

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.